首页 > 最新文献

ANZ Journal of Surgery最新文献

英文 中文
The influence of socioeconomic disadvantage on short- and long-term outcomes after oesophagectomy for cancer: an Australian multicentre study. 社会经济劣势对癌症食道切除术后短期和长期疗效的影响:一项澳大利亚多中心研究。
IF 1.5 4区 医学 Q3 SURGERY Pub Date : 2024-07-23 DOI: 10.1111/ans.19172
Jin-Soo Park, Aleksandra Polikarpova, Steven Leibman, Jerome M Laurence, Garett Smith, Gregory L Falk, Charbel Sandroussi

Background: Socioeconomic status (SES) affects outcomes following surgery for various cancers. There are currently no Australian studies that examine the role of socioeconomic disadvantage on outcomes following oesophagectomy for cancer. This study assessed whether SES was associated with short-term perioperative morbidity, long-term survival, and oncological outcomes following oesophagectomy across three tertiary oesophageal cancer centres in Australia.

Methods: A retrospective cohort study was performed comprising all patients who underwent oesophagectomy for cancer across three Australian centres. Patients were stratified into SES groups using the Index of Relative Socioeconomic Advantage and Disadvantage (IRSAD). Outcomes measured included perioperative complication rates, overall survival, and disease-free survival.

Results: The study cohort was 462 patients, 205 in the lower SES and 257 in the higher SES groups. The lower SES group presented with more advanced oesophageal cancer stage, a higher rate of T3 (52.6% versus 42.7%, P = 0.038) and N2 disease (19.6% versus 10.5%, P = 0.006), and had a higher rate of readmission within 30 days (11.2% versus 5.4%, P = 0.023). There was no difference in overall survival or disease-free survival between groups.

Conclusion: Lower socioeconomic status was associated with more advanced stage and increased risk of early, unplanned readmission following oesophagectomy, but was not associated with a difference in overall or disease-free survival.

背景:社会经济地位(SES)会影响各种癌症手术后的治疗效果。目前,澳大利亚还没有研究探讨社会经济劣势对癌症食道切除术后疗效的影响。本研究评估了澳大利亚三家三级食道癌中心的社会经济地位是否与食道癌切除术后的短期围手术期发病率、长期生存率和肿瘤治疗效果有关:我们进行了一项回顾性队列研究,研究对象包括在澳大利亚三家中心接受食道癌切除术的所有患者。采用相对社会经济优势和劣势指数(IRSAD)将患者分为不同的社会经济地位组。测量结果包括围手术期并发症发生率、总生存率和无病生存率:研究队列中有 462 名患者,其中 205 人属于社会经济地位较低的群体,257 人属于社会经济地位较高的群体。社会经济地位较低组的食管癌分期更晚,T3(52.6% 对 42.7%,P=0.038)和 N2(19.6% 对 10.5%,P=0.006)病变率更高,30 天内再入院率更高(11.2% 对 5.4%,P=0.023)。两组患者的总生存率和无病生存率没有差异:结论:较低的社会经济地位与较晚的分期和食管切除术后早期、非计划再入院的风险增加有关,但与总生存率或无病生存率的差异无关。
{"title":"The influence of socioeconomic disadvantage on short- and long-term outcomes after oesophagectomy for cancer: an Australian multicentre study.","authors":"Jin-Soo Park, Aleksandra Polikarpova, Steven Leibman, Jerome M Laurence, Garett Smith, Gregory L Falk, Charbel Sandroussi","doi":"10.1111/ans.19172","DOIUrl":"https://doi.org/10.1111/ans.19172","url":null,"abstract":"<p><strong>Background: </strong>Socioeconomic status (SES) affects outcomes following surgery for various cancers. There are currently no Australian studies that examine the role of socioeconomic disadvantage on outcomes following oesophagectomy for cancer. This study assessed whether SES was associated with short-term perioperative morbidity, long-term survival, and oncological outcomes following oesophagectomy across three tertiary oesophageal cancer centres in Australia.</p><p><strong>Methods: </strong>A retrospective cohort study was performed comprising all patients who underwent oesophagectomy for cancer across three Australian centres. Patients were stratified into SES groups using the Index of Relative Socioeconomic Advantage and Disadvantage (IRSAD). Outcomes measured included perioperative complication rates, overall survival, and disease-free survival.</p><p><strong>Results: </strong>The study cohort was 462 patients, 205 in the lower SES and 257 in the higher SES groups. The lower SES group presented with more advanced oesophageal cancer stage, a higher rate of T3 (52.6% versus 42.7%, P = 0.038) and N2 disease (19.6% versus 10.5%, P = 0.006), and had a higher rate of readmission within 30 days (11.2% versus 5.4%, P = 0.023). There was no difference in overall survival or disease-free survival between groups.</p><p><strong>Conclusion: </strong>Lower socioeconomic status was associated with more advanced stage and increased risk of early, unplanned readmission following oesophagectomy, but was not associated with a difference in overall or disease-free survival.</p>","PeriodicalId":8158,"journal":{"name":"ANZ Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unilateral chylothorax as a post-acute sequela of SARS-CoV-2 infection 作为 SARS-CoV-2 感染急性后遗症的单侧乳糜胸。
IF 1.5 4区 医学 Q3 SURGERY Pub Date : 2024-07-22 DOI: 10.1111/ans.19121
Andrei M. Belyaev PhD, Shueh H. Lim FRACR, James R. McGiven FRACS
{"title":"Unilateral chylothorax as a post-acute sequela of SARS-CoV-2 infection","authors":"Andrei M. Belyaev PhD,&nbsp;Shueh H. Lim FRACR,&nbsp;James R. McGiven FRACS","doi":"10.1111/ans.19121","DOIUrl":"10.1111/ans.19121","url":null,"abstract":"","PeriodicalId":8158,"journal":{"name":"ANZ Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical outcomes in ileal Crohn's disease complicated by ileosigmoid fistula 回肠克罗恩病并发回肠乙状结肠瘘的手术治疗效果。
IF 1.5 4区 医学 Q3 SURGERY Pub Date : 2024-07-22 DOI: 10.1111/ans.19176
Ashley Jenkin BScH, MBBS, Aleksandra Edmundson PhD, David Clark PhD, FRACS

Background

The management of Crohn's disease (CD) complicated by ileosigmoid fistula (ISF) remains a challenge, and Australian outcomes have not previously been reported.

Methods

A retrospective review of a tertiary colorectal inflammatory bowel disease unit, across public and private sites, from 2005 to 2023 to identify adult patients having undergone operative management of ISF.

Results

Twenty-nine patients underwent surgery for ISF in the study period. Seventeen were male and the median age was 40 years. The pre-operative diagnosis of ISF was made in 76%, and patients were more likely to undergo resectional surgery if the pre-operative diagnosis was made endoscopically. Sixty-nine percent of cases were performed electively, with 76% completed laparoscopically with an 18.5% conversion rate to an open approach. The ISF was oversewn in three patients, repaired primarily in 14 patients, managed with segmental wedge resection in eight patients and resected via an anterior resection in four patients. The rate of stoma formation at the index procedure was 20.7% overall and 22% in patients being acutely managed with steroids. Emergent cases were more likely to be defunctioned with a stoma. Morbidity was 17.2% with a single anastomotic leak.

Conclusion

ISF in CD remains difficult to diagnose pre-operatively, but can be safely managed laparoscopically without formal resection, and with limited use of diverting stoma formation. The specific surgical approach to the sigmoid in ISF is difficult to pre-determine and often requires decisions to be made intra-operatively.

背景:克罗恩病(CD)并发回肠乙状结肠瘘(ISF)的治疗仍然是一项挑战,澳大利亚的治疗结果此前尚未报道:方法:对2005年至2023年期间公立和私立三级结直肠炎症性肠病科室进行回顾性研究,以确定接受过ISF手术治疗的成年患者:研究期间,29 名患者接受了 ISF 手术治疗。其中 17 人为男性,年龄中位数为 40 岁。76%的患者在术前确诊为ISF,如果术前通过内窥镜确诊,患者更有可能接受切除手术。69%的病例是选择性手术,其中76%是腹腔镜手术,18.5%转为开腹手术。3名患者的ISF被切除,14名患者主要进行了修复,8名患者进行了节段性楔形切除,4名患者通过前方切除术切除了ISF。在指数手术中,造口形成率总体为 20.7%,在接受类固醇药物急性治疗的患者中,造口形成率为 22%。急诊病例更有可能使用造口。单次吻合口漏的发病率为17.2%:结论:ISF 在 CD 中仍然难以在术前诊断,但可以通过腹腔镜安全处理,无需进行正式切除,只需有限地使用分流造口。ISF患者乙状结肠的具体手术方式很难预先确定,往往需要在术中做出决定。
{"title":"Surgical outcomes in ileal Crohn's disease complicated by ileosigmoid fistula","authors":"Ashley Jenkin BScH, MBBS,&nbsp;Aleksandra Edmundson PhD,&nbsp;David Clark PhD, FRACS","doi":"10.1111/ans.19176","DOIUrl":"10.1111/ans.19176","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The management of Crohn's disease (CD) complicated by ileosigmoid fistula (ISF) remains a challenge, and Australian outcomes have not previously been reported.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective review of a tertiary colorectal inflammatory bowel disease unit, across public and private sites, from 2005 to 2023 to identify adult patients having undergone operative management of ISF.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-nine patients underwent surgery for ISF in the study period. Seventeen were male and the median age was 40 years. The pre-operative diagnosis of ISF was made in 76%, and patients were more likely to undergo resectional surgery if the pre-operative diagnosis was made endoscopically. Sixty-nine percent of cases were performed electively, with 76% completed laparoscopically with an 18.5% conversion rate to an open approach. The ISF was oversewn in three patients, repaired primarily in 14 patients, managed with segmental wedge resection in eight patients and resected via an anterior resection in four patients. The rate of stoma formation at the index procedure was 20.7% overall and 22% in patients being acutely managed with steroids. Emergent cases were more likely to be defunctioned with a stoma. Morbidity was 17.2% with a single anastomotic leak.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>ISF in CD remains difficult to diagnose pre-operatively, but can be safely managed laparoscopically without formal resection, and with limited use of diverting stoma formation. The specific surgical approach to the sigmoid in ISF is difficult to pre-determine and often requires decisions to be made intra-operatively.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8158,"journal":{"name":"ANZ Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ans.19176","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Osteoid osteoma in the distal radius mimicking Brodie's abscess 模仿布罗迪脓肿的桡骨远端骨样骨瘤。
IF 1.5 4区 医学 Q3 SURGERY Pub Date : 2024-07-17 DOI: 10.1111/ans.19141
Mahsa Sarrami BMed, MS, Brahman Shankar Sivakumar MBBS, BSci (Med), MS, MSc, FRACS, FAOrthA, PFE, Richard Lawson MBBS (Hons 1 Syd), FRACS, FAOrthA
{"title":"Osteoid osteoma in the distal radius mimicking Brodie's abscess","authors":"Mahsa Sarrami BMed, MS,&nbsp;Brahman Shankar Sivakumar MBBS, BSci (Med), MS, MSc, FRACS, FAOrthA, PFE,&nbsp;Richard Lawson MBBS (Hons 1 Syd), FRACS, FAOrthA","doi":"10.1111/ans.19141","DOIUrl":"10.1111/ans.19141","url":null,"abstract":"","PeriodicalId":8158,"journal":{"name":"ANZ Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141625760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Consensus statement: support for supervisors of surgical training in Australia and Aotearoa New Zealand 共识声明:为澳大利亚和新西兰的外科培训导师提供支持。
IF 1.5 4区 医学 Q3 SURGERY Pub Date : 2024-07-17 DOI: 10.1111/ans.19111
Deborah Paltridge BAppSc(Phys), MHSc(Ed), FRACS Hon, Jenepher Martin MBBS, MS, MEd, DEd, FRACS, James Churchill MBBS, BMedSc, FRACS, MFSTEd, AFHEA, Richard Grills MBBS, FRACS, Benjamin Loveday MBChB, PhD, FRACS, Romi Das Gupta MBChB, PhD, FRACS, Sarah Catherine Rennie BMSc (Hons1), MBChB, PhD, FRSCEd (Medal), FRACS, FACS

The Supervisor Support Consensus Statement has been developed after consultation with supervisors of surgical training for the Royal Australasian College of Surgeons (RACS) programmes in Australia and Aotearoa New Zealand and other key stakeholders. Six key areas have been recognized with specific recommendations crafted to improve the support and recognition of Supervisors: 1. Clarity of role, 2. Education and Training, 3. Local support, 4. RACS support, 5. Recognition and valuing of the Supervisor role, 6. Risk Management. The purpose of this consensus statement is to clearly articulate supervisor opinions on the support they require to undertake this important role. It has been produced by an independent writing group of experienced surgical supervisors and educators, with support from RACS education department. The consensus statement is a response to a needs assessment of supervisors of surgical training. The statements in this consensus document have been generated from comments and feedback from supervisors that have been refined through process of extensive consultation using a Delphi methodology. We advise specialty training Committees consider these statements and mandate them as part of their accreditation of terms. The role of the supervisor of training requires greater recognition, and incorporation in the Enterprise Bargaining Agreement (EBA) in Australia and the ASMS Te Whatu Ora SECA in Aotearoa New Zealand would ensure the provisions in this document are enacted. The six areas identified have transferability to other specialities and countries and are valuable when considering how to support supervisors involved in training our next generation of specialist doctors.

导师支持共识声明是在咨询了澳大利亚和新西兰皇家澳大拉西亚外科学院 (RACS) 课程的外科培训导师以及其他主要利益相关者后制定的。声明确认了六个关键领域,并提出了具体建议,以改善对督导的支持和认可:1.角色明确;2.教育和培训;3.地方支持;4.RACS 支持;5.认可和重视督导的角色;6.风险管理。本共识声明的目的是明确阐述督导在履行这一重要职责时所需要的支持。它是由经验丰富的外科督导和教育工作者组成的独立写作小组在 RACS 教育部门的支持下完成的。该共识声明是对外科培训督导需求评估的回应。本共识文件中的声明是根据督导人员的意见和反馈编制而成的,并通过德尔菲法进行广泛协商后加以完善。我们建议专科培训委员会考虑这些声明,并将其作为认证条款的一部分。培训督导的作用需要得到更多的认可,将其纳入澳大利亚的《企业谈判协议》(EBA)和新西兰的《ASMS Te Whatu Ora SECA》将确保本文件中的规定得以实施。所确定的六个领域可适用于其他专科和国家,在考虑如何为参与培训下一代专科医生的督导人员提供支持时非常有价值。
{"title":"Consensus statement: support for supervisors of surgical training in Australia and Aotearoa New Zealand","authors":"Deborah Paltridge BAppSc(Phys), MHSc(Ed), FRACS Hon,&nbsp;Jenepher Martin MBBS, MS, MEd, DEd, FRACS,&nbsp;James Churchill MBBS, BMedSc, FRACS, MFSTEd, AFHEA,&nbsp;Richard Grills MBBS, FRACS,&nbsp;Benjamin Loveday MBChB, PhD, FRACS,&nbsp;Romi Das Gupta MBChB, PhD, FRACS,&nbsp;Sarah Catherine Rennie BMSc (Hons1), MBChB, PhD, FRSCEd (Medal), FRACS, FACS","doi":"10.1111/ans.19111","DOIUrl":"10.1111/ans.19111","url":null,"abstract":"<p>The Supervisor Support Consensus Statement has been developed after consultation with supervisors of surgical training for the Royal Australasian College of Surgeons (RACS) programmes in Australia and Aotearoa New Zealand and other key stakeholders. Six key areas have been recognized with specific recommendations crafted to improve the support and recognition of Supervisors: 1. Clarity of role, 2. Education and Training, 3. Local support, 4. RACS support, 5. Recognition and valuing of the Supervisor role, 6. Risk Management. The purpose of this consensus statement is to clearly articulate supervisor opinions on the support they require to undertake this important role. It has been produced by an independent writing group of experienced surgical supervisors and educators, with support from RACS education department. The consensus statement is a response to a needs assessment of supervisors of surgical training. The statements in this consensus document have been generated from comments and feedback from supervisors that have been refined through process of extensive consultation using a Delphi methodology. We advise specialty training Committees consider these statements and mandate them as part of their accreditation of terms. The role of the supervisor of training requires greater recognition, and incorporation in the Enterprise Bargaining Agreement (EBA) in Australia and the ASMS Te Whatu Ora SECA in Aotearoa New Zealand would ensure the provisions in this document are enacted. The six areas identified have transferability to other specialities and countries and are valuable when considering how to support supervisors involved in training our next generation of specialist doctors.</p>","PeriodicalId":8158,"journal":{"name":"ANZ Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ans.19111","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141625759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A combined nutritional risk index and carcinoembryonic antigen score predicts the outcome in radically resected colorectal cancer. 营养风险指数和癌胚抗原综合评分可预测根治性切除大肠癌的预后。
IF 1.5 4区 医学 Q3 SURGERY Pub Date : 2024-07-17 DOI: 10.1111/ans.19161
Guanzhou Chen, Jiang Xie, Panhua Li, Qin Wang, Qianwen Ye, Shouhan Feng

Background: Nutritional risk index (NRI) and carcinoembryonic antigen (CEA) are useful prognostic markers in colorectal cancer (CRC); however, the prognostic value of a combination of the NRI and CEA, namely, the NRI and CEA score (NCS), needs further investigation.

Methods: Stage I-III CRC patients were collected and then divided into three subgroups by counting the NCS: NCS 1: high NRI with normal CEA; NCS 2: high NRI with elevated CEA or low NRI with normal CEA; and NCS 3: low NRI with elevated CEA. The differences in outcome, counted as disease-free survival (DFS) and overall survival (OS), were tested among the subgroups.

Results: A total of 285 patients were enrolled, with 108 in NCS 1, 118 in NCS 2 and 59 in NCS 3. Patient features, including age, tumour deposit, T stage, N stage and TNM stage, were significantly different in the NCS subgroups. Both the DFS (log-rank = 26.06, P<0.001) and OS (log-rank = 39.10, P<0.001) were significant in different NCS subgroups, even in maximum tumour diameter ≤4 cm cases (DFS: log-rank = 21.42, P<0.001; OS: log-rank = 30.95, P<0.001), and NCS 1 patients displayed the best outcome compared with the rest of the subgroups. NCS was also found to be an independent risk factor for both DFS and OS.

Conclusions: NCS was a useful prognostic indicator in stages I-III CRC patients.

背景:营养风险指数(NRI)和癌胚抗原(CEA)是结直肠癌(CRC)有用的预后标志物;然而,NRI和CEA的组合,即NRI和CEA评分(NCS)的预后价值需要进一步研究:方法:收集 I-III 期 CRC 患者,然后通过计算 NCS 将其分为三个亚组:NCS 1:NRI 高,CEA 正常;NCS 2:NRI 高,CEA 升高或 NRI 低,CEA 正常;NCS 3:NRI 低,CEA 升高。测试了不同亚组之间无病生存期(DFS)和总生存期(OS)的结果差异:共有 285 例患者入组,其中 108 例属于 NCS 1,118 例属于 NCS 2,59 例属于 NCS 3。NCS亚组的患者特征,包括年龄、肿瘤沉积、T分期、N分期和TNM分期,均有显著差异。DFS(log-rank = 26.06,PConclusions:NCS是I-III期CRC患者的一个有用的预后指标。
{"title":"A combined nutritional risk index and carcinoembryonic antigen score predicts the outcome in radically resected colorectal cancer.","authors":"Guanzhou Chen, Jiang Xie, Panhua Li, Qin Wang, Qianwen Ye, Shouhan Feng","doi":"10.1111/ans.19161","DOIUrl":"https://doi.org/10.1111/ans.19161","url":null,"abstract":"<p><strong>Background: </strong>Nutritional risk index (NRI) and carcinoembryonic antigen (CEA) are useful prognostic markers in colorectal cancer (CRC); however, the prognostic value of a combination of the NRI and CEA, namely, the NRI and CEA score (NCS), needs further investigation.</p><p><strong>Methods: </strong>Stage I-III CRC patients were collected and then divided into three subgroups by counting the NCS: NCS 1: high NRI with normal CEA; NCS 2: high NRI with elevated CEA or low NRI with normal CEA; and NCS 3: low NRI with elevated CEA. The differences in outcome, counted as disease-free survival (DFS) and overall survival (OS), were tested among the subgroups.</p><p><strong>Results: </strong>A total of 285 patients were enrolled, with 108 in NCS 1, 118 in NCS 2 and 59 in NCS 3. Patient features, including age, tumour deposit, T stage, N stage and TNM stage, were significantly different in the NCS subgroups. Both the DFS (log-rank = 26.06, P<0.001) and OS (log-rank = 39.10, P<0.001) were significant in different NCS subgroups, even in maximum tumour diameter ≤4 cm cases (DFS: log-rank = 21.42, P<0.001; OS: log-rank = 30.95, P<0.001), and NCS 1 patients displayed the best outcome compared with the rest of the subgroups. NCS was also found to be an independent risk factor for both DFS and OS.</p><p><strong>Conclusions: </strong>NCS was a useful prognostic indicator in stages I-III CRC patients.</p>","PeriodicalId":8158,"journal":{"name":"ANZ Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141625758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of thyroidectomy in symptomatic, euthyroid Hashimoto's patients: a case control study. 对无症状、甲状腺功能正常的桥本氏病患者进行甲状腺切除术的结果:一项病例对照研究。
IF 1.5 4区 医学 Q3 SURGERY Pub Date : 2024-07-16 DOI: 10.1111/ans.19155
Hazel Serrao-Brown, Amna Saadi, Jessica Wong, Alexander Papachristos, Mark Sywak, Stan Sidhu

Background: Hashimoto's thyroiditis (HT) is managed with thyroid hormone replacement to maintain a euthyroid state. A subset of patients have refractory symptoms, which improve with thyroidectomy (TT). There remains a reluctance to proceed with surgery due to perceptions of complications, and limited data availability regarding improvements in quality of life (QoL). This retrospective case control study aims to analyse the outcomes and QoL scores for symptomatic euthyroid HT patients who underwent TT.

Methods: Thirty euthyroid patients who underwent TT for the management of HT between 2017 and 2022 were identified. An age-matched control group of patients who underwent TT for symptomatic multinodular goitre (MNG) were randomly selected. Demographics, biochemistry, histology, outcomes, and pre- and post-operative SF-36 and ThyPRO-39 scores were compared between groups.

Results: There were no surgical complications in the HT group, whilst two MNG patients had complications. There was a similar rate of parathyroid auto-transplantation in both groups, more glands were transplanted in the HT group. There was a significant difference in pre- and post-operative QoL scores for both groups. Comparison revealed a significant improvement in hyperthyroid symptoms, social life and daily life scores in the HT group. There was a significant difference in pre- and post-operative anti-TPO, anti-TG and TSH levels in the HT group.

Conclusion: Patients with symptomatic Hashimoto's thyroiditis, despite being euthyroid, may benefit from total thyroidectomy however this remains under-utilized. This study demonstrated that thyroidectomy was associated with an improvement in validated post-operative quality of life scores and was not associated with increased complication rates for appropriately selected patients.

背景:桥本氏甲状腺炎(HT)需要通过补充甲状腺激素来维持甲状腺功能正常。一部分患者有难治性症状,甲状腺切除术(TT)可改善这些症状。由于认为会出现并发症,且有关生活质量(QoL)改善情况的数据有限,患者仍不愿意接受手术治疗。这项回顾性病例对照研究旨在分析接受TT的无症状甲状腺功能亢进患者的治疗效果和QoL评分:确定了2017年至2022年间接受TT治疗甲状腺功能亢进的30名甲状腺功能亢进患者。随机选取因症状性多结节性甲状腺肿(MNG)接受TT治疗的患者作为年龄匹配的对照组。对两组患者的人口统计学、生物化学、组织学、疗效、术前术后SF-36和ThyPRO-39评分进行比较:结果:HT组无手术并发症,而MNG组有两名患者出现并发症。两组患者的甲状旁腺自体移植率相似,但HT组移植的腺体更多。两组患者术前和术后的 QoL 评分有明显差异。比较显示,HT组的甲状腺功能亢进症状、社交生活和日常生活评分明显改善。HT组患者术前和术后抗TPO、抗TG和促甲状腺激素水平有明显差异:结论:有症状的桥本氏甲状腺炎患者尽管是甲状腺功能亢进,但仍可从全甲状腺切除术中获益,但这种方法仍未得到充分利用。这项研究表明,甲状腺切除术与术后生活质量有效评分的改善有关,而且对于经过适当选择的患者来说,甲状腺切除术与并发症发生率的增加无关。
{"title":"Outcomes of thyroidectomy in symptomatic, euthyroid Hashimoto's patients: a case control study.","authors":"Hazel Serrao-Brown, Amna Saadi, Jessica Wong, Alexander Papachristos, Mark Sywak, Stan Sidhu","doi":"10.1111/ans.19155","DOIUrl":"https://doi.org/10.1111/ans.19155","url":null,"abstract":"<p><strong>Background: </strong>Hashimoto's thyroiditis (HT) is managed with thyroid hormone replacement to maintain a euthyroid state. A subset of patients have refractory symptoms, which improve with thyroidectomy (TT). There remains a reluctance to proceed with surgery due to perceptions of complications, and limited data availability regarding improvements in quality of life (QoL). This retrospective case control study aims to analyse the outcomes and QoL scores for symptomatic euthyroid HT patients who underwent TT.</p><p><strong>Methods: </strong>Thirty euthyroid patients who underwent TT for the management of HT between 2017 and 2022 were identified. An age-matched control group of patients who underwent TT for symptomatic multinodular goitre (MNG) were randomly selected. Demographics, biochemistry, histology, outcomes, and pre- and post-operative SF-36 and ThyPRO-39 scores were compared between groups.</p><p><strong>Results: </strong>There were no surgical complications in the HT group, whilst two MNG patients had complications. There was a similar rate of parathyroid auto-transplantation in both groups, more glands were transplanted in the HT group. There was a significant difference in pre- and post-operative QoL scores for both groups. Comparison revealed a significant improvement in hyperthyroid symptoms, social life and daily life scores in the HT group. There was a significant difference in pre- and post-operative anti-TPO, anti-TG and TSH levels in the HT group.</p><p><strong>Conclusion: </strong>Patients with symptomatic Hashimoto's thyroiditis, despite being euthyroid, may benefit from total thyroidectomy however this remains under-utilized. This study demonstrated that thyroidectomy was associated with an improvement in validated post-operative quality of life scores and was not associated with increased complication rates for appropriately selected patients.</p>","PeriodicalId":8158,"journal":{"name":"ANZ Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative outcomes in patients who undergo neoadjuvant chemoradiotherapy versus chemotherapy versus up-front surgery in patients with oesophageal cancer. 食道癌患者接受新辅助化放疗、化疗和先期手术的围手术期疗效。
IF 1.5 4区 医学 Q3 SURGERY Pub Date : 2024-07-12 DOI: 10.1111/ans.19159
Nazim Bhimani, David Mitchell, Cameron Law, Steven Leibman, Garett Smith

Background: Oesophagectomy is the mainstay of curative treatment for oesophageal cancer. The role of neoadjuvant therapy has evolved over time as evidence for its survival benefit comes to hand. Clinician reluctance to offer patients neoadjuvant therapy may be based on the perception that patients receiving treatment before surgery may be exposed to a greater risk of perioperative complications. The aim of this study was to examine short-term outcomes in patients who undergo neoadjuvant therapy versus up-front surgery in patients with oesophageal cancer.

Methods: This was a retrospective cohort study of prospectively collated data from 2001 to 2020 of patients undergoing resection for oesophageal cancer. Patients who had neoadjuvant chemoradiotherapy, chemotherapy and up-front surgery were compared for perioperative morbidity (via the Clavien-Dindo classification), length of stay, unplanned readmission, and 30- and 90-day mortality. Logistic regression was performed to predict perioperative morbidity following surgery.

Results: In total, 284 patients underwent an oesophagectomy. Most patients received neoadjuvant treatment (41% received chemoradiotherapy (117/284), 33% received chemotherapy (93/284)), and 26% of patients received up-front surgery (74/284). Patients who received neoadjuvant chemoradiotherapy or up-front surgery were more likely to have a complication (57%, 67/117 and 57%, 43/74) than patients who received neoadjuvant chemotherapy only (38%, 35/93, P = 0.009). The 30- and 90-day mortality rates were 1.4% (n = 4) and 2.8% (n = 8), respectively, with no difference between the use of neoadjuvant therapy.

Conclusion: In this series, we found that patients who received neoadjuvant treatment could undergo oesophagectomy with curative intent with acceptable postoperative morbidity and mortality.

背景:食管切除术是食管癌根治性治疗的主要手段。随着时间的推移,新辅助治疗的作用也在不断变化,因为有证据表明新辅助治疗对患者的生存有利。临床医生之所以不愿意为患者提供新辅助治疗,可能是认为患者在手术前接受治疗可能会增加围手术期并发症的风险。本研究旨在探讨食道癌患者接受新辅助治疗与手术治疗的短期疗效:这是一项回顾性队列研究,研究对象是2001年至2020年期间接受食道癌切除术的患者。研究比较了接受新辅助化放疗、化疗和先期手术的患者的围手术期发病率(根据克拉维恩-丁多分类法)、住院时间、非计划再入院、30 天和 90 天死亡率。采用逻辑回归法预测手术后围手术期的发病率:共有284名患者接受了食管切除术。大多数患者接受了新辅助治疗(41%接受了化放疗(117/284),33%接受了化疗(93/284)),26%的患者接受了前期手术(74/284)。与仅接受新辅助化疗的患者(38%,35/93,P = 0.009)相比,接受新辅助化放疗或前期手术的患者更容易出现并发症(57%,67/117;57%,43/74)。30天和90天的死亡率分别为1.4%(4人)和2.8%(8人),采用新辅助疗法的患者之间没有差异:在这一系列研究中,我们发现接受新辅助治疗的患者可以接受治愈性食管切除术,术后发病率和死亡率均可接受。
{"title":"Perioperative outcomes in patients who undergo neoadjuvant chemoradiotherapy versus chemotherapy versus up-front surgery in patients with oesophageal cancer.","authors":"Nazim Bhimani, David Mitchell, Cameron Law, Steven Leibman, Garett Smith","doi":"10.1111/ans.19159","DOIUrl":"https://doi.org/10.1111/ans.19159","url":null,"abstract":"<p><strong>Background: </strong>Oesophagectomy is the mainstay of curative treatment for oesophageal cancer. The role of neoadjuvant therapy has evolved over time as evidence for its survival benefit comes to hand. Clinician reluctance to offer patients neoadjuvant therapy may be based on the perception that patients receiving treatment before surgery may be exposed to a greater risk of perioperative complications. The aim of this study was to examine short-term outcomes in patients who undergo neoadjuvant therapy versus up-front surgery in patients with oesophageal cancer.</p><p><strong>Methods: </strong>This was a retrospective cohort study of prospectively collated data from 2001 to 2020 of patients undergoing resection for oesophageal cancer. Patients who had neoadjuvant chemoradiotherapy, chemotherapy and up-front surgery were compared for perioperative morbidity (via the Clavien-Dindo classification), length of stay, unplanned readmission, and 30- and 90-day mortality. Logistic regression was performed to predict perioperative morbidity following surgery.</p><p><strong>Results: </strong>In total, 284 patients underwent an oesophagectomy. Most patients received neoadjuvant treatment (41% received chemoradiotherapy (117/284), 33% received chemotherapy (93/284)), and 26% of patients received up-front surgery (74/284). Patients who received neoadjuvant chemoradiotherapy or up-front surgery were more likely to have a complication (57%, 67/117 and 57%, 43/74) than patients who received neoadjuvant chemotherapy only (38%, 35/93, P = 0.009). The 30- and 90-day mortality rates were 1.4% (n = 4) and 2.8% (n = 8), respectively, with no difference between the use of neoadjuvant therapy.</p><p><strong>Conclusion: </strong>In this series, we found that patients who received neoadjuvant treatment could undergo oesophagectomy with curative intent with acceptable postoperative morbidity and mortality.</p>","PeriodicalId":8158,"journal":{"name":"ANZ Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Initial experience of minimally invasive mesh explantation for inguinodynia 微创网片剥离治疗腹股沟扩张症的初步经验。
IF 1.5 4区 医学 Q3 SURGERY Pub Date : 2024-07-12 DOI: 10.1111/ans.19158
Jonathan Wiener BHSc, MBBS, Elan Novis BSc, MBBS, MS, FRACS, Joel Rabindran BSc (Hons 1), MBBS, FRACS, Douglas Fenton-Lee MBBS, FRACS

Background

Chronic pain after minimally invasive inguinal hernia repair with mesh can have debilitating effects on quality of life (QOL), limiting daily activities and ability to work. Many medical and surgical options for treatment have been proposed, however there is no consensus on the role of mesh explantation in the management of these patients.

Methods

We performed a retrospective review of all patients who underwent groin mesh removal by robotic or laparoscopic approach from July 2012 to July 2023 at our institution. Patients were interviewed post-operatively to determine their overall pain scores and QOL was assessed using the Carolinas Comfort Scale (CCS) Questionnaire. Patient characteristics, operative times, pre-operative imaging techniques and analgesia use was also recorded.

Results

Twenty-two patients underwent groin mesh removal for chronic pain, including 12 robotic and 10 laparoscopic operations. The mean pre-operative pain score in all patients was 7.6/10 compared to 4.0/10 post-operatively. The mean post-operative CCS score was 24, indicating moderate discomfort. Four patients demonstrated CCS scores <11 indicating no discomfort and no patients demonstrated CCS scores >90, indicating severe debilitating discomfort. The majority of patients had a reduction or total cessation of analgesia intake post-operatively.

Conclusion

Both laparoscopic and robotic mesh explantation for treatment of chronic pain post-inguinal hernia repair is safe and effective in achieving a reduction in pain and reducing the need for long-term analgesia.

背景:使用网片进行微创腹股沟疝修补术后的慢性疼痛会影响患者的生活质量(QOL),限制患者的日常活动和工作能力。目前已提出了许多药物和手术治疗方案,但对于网片剥离在这些患者治疗中的作用还没有达成共识:我们对 2012 年 7 月至 2023 年 7 月在本院接受机器人或腹腔镜腹股沟网片切除术的所有患者进行了回顾性研究。我们在术后对患者进行了访谈,以确定他们的总体疼痛评分,并使用卡罗莱纳舒适度量表(CCS)问卷对患者的 QOL 进行了评估。此外,还记录了患者特征、手术时间、术前成像技术和镇痛剂使用情况:22名患者因慢性疼痛接受了腹股沟网片切除术,其中包括12例机器人手术和10例腹腔镜手术。所有患者术前的平均疼痛评分为 7.6/10,而术后为 4.0/10。术后 CCS 评分平均为 24 分,显示中度不适。四名患者的 CCS 评分为 90 分,表明存在严重的衰弱性不适。大多数患者术后减少或完全停止了镇痛剂的摄入:结论:腹腔镜和机器人网片剥离术治疗腹股沟疝修补术后的慢性疼痛既安全又有效,可减轻疼痛并减少长期镇痛的需求。
{"title":"Initial experience of minimally invasive mesh explantation for inguinodynia","authors":"Jonathan Wiener BHSc, MBBS,&nbsp;Elan Novis BSc, MBBS, MS, FRACS,&nbsp;Joel Rabindran BSc (Hons 1), MBBS, FRACS,&nbsp;Douglas Fenton-Lee MBBS, FRACS","doi":"10.1111/ans.19158","DOIUrl":"10.1111/ans.19158","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic pain after minimally invasive inguinal hernia repair with mesh can have debilitating effects on quality of life (QOL), limiting daily activities and ability to work. Many medical and surgical options for treatment have been proposed, however there is no consensus on the role of mesh explantation in the management of these patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed a retrospective review of all patients who underwent groin mesh removal by robotic or laparoscopic approach from July 2012 to July 2023 at our institution. Patients were interviewed post-operatively to determine their overall pain scores and QOL was assessed using the Carolinas Comfort Scale (CCS) Questionnaire. Patient characteristics, operative times, pre-operative imaging techniques and analgesia use was also recorded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-two patients underwent groin mesh removal for chronic pain, including 12 robotic and 10 laparoscopic operations. The mean pre-operative pain score in all patients was 7.6/10 compared to 4.0/10 post-operatively. The mean post-operative CCS score was 24, indicating moderate discomfort. Four patients demonstrated CCS scores &lt;11 indicating no discomfort and no patients demonstrated CCS scores &gt;90, indicating severe debilitating discomfort. The majority of patients had a reduction or total cessation of analgesia intake post-operatively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Both laparoscopic and robotic mesh explantation for treatment of chronic pain post-inguinal hernia repair is safe and effective in achieving a reduction in pain and reducing the need for long-term analgesia.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8158,"journal":{"name":"ANZ Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The complexities of establishing a surgical multi-centre registry in Australia: challenges, and possible solution 在澳大利亚建立外科多中心登记处的复杂性:挑战和可能的解决方案。
IF 1.5 4区 医学 Q3 SURGERY Pub Date : 2024-07-12 DOI: 10.1111/ans.19157
Adam Ofri BMed, MS, FRACS, MAdvSurg, Andrew J. Spillane BMBS, MD, FRACS
<p>Multi-institutional research gives a more representative appraisal of surgical practice and enables statistical power to answer relevant questions in randomized controlled trials and other research methodologies. In Australia, breast cancer is the most common non-skin malignancy and significant multi-institutional research is consistently being undertaken, predominantly under the auspices of the collaborative clinical trials group Breast Cancer Trials (BCT). A major project underwritten by the BCT Clinical Research Fellowship was to develop the Australian and New Zealand (ANZ) Targeted Axillary Dissection (TAD) Registry. TAD is the localisation and removal of previously metastatic axillary lymph nodes usually marked at diagnosis with a radiologically visible marker clip, as well as the removal of identified sentinel nodes, after neoadjuvant systemic therapy. The aim of the TAD Registry was to create a de-identified record of all TAD procedures across ANZ, to facilitate an understanding of how as a relatively new and nuanced technique, TAD is being implemented and interpreted. This was conceptualized with the BreastSurgANZ leadership team as a priority area for research and BreastSurgANZ has been strongly supportive in its development and implementation.</p><p>However, what the investigators considered to be a low-risk, easy to facilitate short-term registry, has taken over 12 months of significant effort, and have still fallen short at this current time. The registry was planned to be running across multiple BreastSurgANZ-affiliated ANZ institutions from the fifth of February 2024. Unfortunately at this date, half of the individual site approvals were still progressing. Plans to roll the 12 month pilot registry into an ongoing audit seem extremely improbable because of the challenges.</p><p>This article aims to draw attention to the difficulties in establishing a simple multi-centre de-identified finite duration registry. By flagging a few key issues, the hope is that this could prompt discussions that leads to significant improvement and efficiencies in the way we share de-identified data between institutions and states. By achieving that, we could easily improve Australia's international research representation and improve patient care.</p><p>When applying for Australian ethical approval in multi-centre research, an excellent development is the National Mutual Acceptance (NMA) scheme.<span><sup>1</sup></span> This scheme, for multi-centre ethical and scientific research, enables a single ethics application that once approved, is applicable for other Australian state and territory-certified public health organizations. After Ethical approval, for investigators to open their study at their institution, they require local research governance, administered by the process of site specific assessment (SSA) which signs off local willingness, resources and capabilities to participate.<span><sup>2</sup></span></p><p>Most patients want to be treated b
多中心研究项目在促进科学理解和解决复杂的研究问题方面大有可为。然而,在通往成功的道路上往往障碍重重,这极大地挫伤了研究人员的热情。通过为低风险登记建立一个澳大利亚中央伦理和管理委员会,我们可以大大提高现有的研究成果。亚当-奥弗里(Adam Ofri):构思;数据整理;正式分析;资金获取;调查;方法论;项目管理;资源;软件;监督;验证;可视化;写作-原稿;写作-审阅和编辑。安德鲁-J-斯皮兰概念化;数据整理;正式分析;资金获取;调查;方法;项目管理;资源;软件;监督;验证;可视化;写作--原稿;写作--审阅和编辑。
{"title":"The complexities of establishing a surgical multi-centre registry in Australia: challenges, and possible solution","authors":"Adam Ofri BMed, MS, FRACS, MAdvSurg,&nbsp;Andrew J. Spillane BMBS, MD, FRACS","doi":"10.1111/ans.19157","DOIUrl":"10.1111/ans.19157","url":null,"abstract":"&lt;p&gt;Multi-institutional research gives a more representative appraisal of surgical practice and enables statistical power to answer relevant questions in randomized controlled trials and other research methodologies. In Australia, breast cancer is the most common non-skin malignancy and significant multi-institutional research is consistently being undertaken, predominantly under the auspices of the collaborative clinical trials group Breast Cancer Trials (BCT). A major project underwritten by the BCT Clinical Research Fellowship was to develop the Australian and New Zealand (ANZ) Targeted Axillary Dissection (TAD) Registry. TAD is the localisation and removal of previously metastatic axillary lymph nodes usually marked at diagnosis with a radiologically visible marker clip, as well as the removal of identified sentinel nodes, after neoadjuvant systemic therapy. The aim of the TAD Registry was to create a de-identified record of all TAD procedures across ANZ, to facilitate an understanding of how as a relatively new and nuanced technique, TAD is being implemented and interpreted. This was conceptualized with the BreastSurgANZ leadership team as a priority area for research and BreastSurgANZ has been strongly supportive in its development and implementation.&lt;/p&gt;&lt;p&gt;However, what the investigators considered to be a low-risk, easy to facilitate short-term registry, has taken over 12 months of significant effort, and have still fallen short at this current time. The registry was planned to be running across multiple BreastSurgANZ-affiliated ANZ institutions from the fifth of February 2024. Unfortunately at this date, half of the individual site approvals were still progressing. Plans to roll the 12 month pilot registry into an ongoing audit seem extremely improbable because of the challenges.&lt;/p&gt;&lt;p&gt;This article aims to draw attention to the difficulties in establishing a simple multi-centre de-identified finite duration registry. By flagging a few key issues, the hope is that this could prompt discussions that leads to significant improvement and efficiencies in the way we share de-identified data between institutions and states. By achieving that, we could easily improve Australia's international research representation and improve patient care.&lt;/p&gt;&lt;p&gt;When applying for Australian ethical approval in multi-centre research, an excellent development is the National Mutual Acceptance (NMA) scheme.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; This scheme, for multi-centre ethical and scientific research, enables a single ethics application that once approved, is applicable for other Australian state and territory-certified public health organizations. After Ethical approval, for investigators to open their study at their institution, they require local research governance, administered by the process of site specific assessment (SSA) which signs off local willingness, resources and capabilities to participate.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Most patients want to be treated b","PeriodicalId":8158,"journal":{"name":"ANZ Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ans.19157","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
ANZ Journal of Surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1